Discontinue use if liver dysfunction has emerged. Serious allergic reactions including angioneurotic oedema & anaphylaxis, acute generalized exanthematous pustulosis (AGEP) & DRESS. Observe signs of superinfection w/ non-susceptible organisms including fungi. Patients w/ congenital or documented QT prolongation, electrolyte disturbance, particularly in case of hypokalaemia & hypomagnesemia, & clinically relevant bradycardia, cardiac arrhythmia or severe cardiac insufficiency; currently receiving treatment w/ other active substance prolonging QT interval eg, Classes Ia & III antiarrhythmics, cisapride & terfenadine.
Clostridium difficile associated diarrhoea (CDAD). Diabetic patients. Fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltase insufficiency. Immediately perform LFTs if signs & symptoms of liver dysfunction occurs, eg, rapid developing asthenia associated w/ jaundice, dark urine, bleeding tendency or hepatic encephalopathy. Not to co-administer w/ ergot derivatives. Patients w/ severe renal impairment (GFR <10 mL/min); significant hepatic disease. Not to be given to patients suffering from severe liver disease. Pregnancy. Discontinue lactation or discontinue/abstain from therapy. Childn <6 mth.
Sign Out
